Skip to main content
. Author manuscript; available in PMC: 2019 Jan 2.
Published in final edited form as: Mol Pharm. 2017 Dec 12;15(1):279–288. doi: 10.1021/acs.molpharmaceut.7b00957

Figure 1.

Figure 1

A, Chemical structure of ritonavir. B, Scaffold used as a template for synthesis of CYP3A4 inhibitors: pyridine nitrogen is the heme ligand, R1 and R2 are variable side groups, and Boc is the terminal moiety. C and D, Two most potent inhibitors of CYP3A4 from the first